3093 related articles for article (PubMed ID: 16959170)
21. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
22. Home treatment for mental health problems: a systematic review.
Burns T; Knapp M; Catty J; Healey A; Henderson J; Watt H; Wright C
Health Technol Assess; 2001; 5(15):1-139. PubMed ID: 11532236
[TBL] [Abstract][Full Text] [Related]
23. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
25. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
[TBL] [Abstract][Full Text] [Related]
26. A systematic overview of chemotherapy effects in breast cancer.
Bergh J; Jönsson PE; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):253-81. PubMed ID: 11441936
[TBL] [Abstract][Full Text] [Related]
27. Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?
Naeim A; Keeler EB
Breast Cancer Res Treat; 2005 Nov; 94(2):95-103. PubMed ID: 16261407
[TBL] [Abstract][Full Text] [Related]
28. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
29. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
30. Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(10):1-234. PubMed ID: 32284770
[TBL] [Abstract][Full Text] [Related]
31. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.
Eifel P; Axelson JA; Costa J; Crowley J; Curran WJ; Deshler A; Fulton S; Hendricks CB; Kemeny M; Kornblith AB; Louis TA; Markman M; Mayer R; Roter D
J Natl Cancer Inst; 2001 Jul; 93(13):979-89. PubMed ID: 11438563
[TBL] [Abstract][Full Text] [Related]
32. Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.
Imai H; Kuroi K; Ohsumi S; Ono M; Shimozuma K
Breast Cancer; 2007; 14(1):81-7. PubMed ID: 17245000
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant therapy for breast cancer.
NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
[TBL] [Abstract][Full Text] [Related]
34. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
35. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.
Wilson J; Yao GL; Raftery J; Bohlius J; Brunskill S; Sandercock J; Bayliss S; Moss P; Stanworth S; Hyde C
Health Technol Assess; 2007 Apr; 11(13):1-202, iii-iv. PubMed ID: 17408534
[TBL] [Abstract][Full Text] [Related]
36. Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis.
Reeve K; On BI; Havla J; Burns J; Gosteli-Peter MA; Alabsawi A; Alayash Z; Götschi A; Seibold H; Mansmann U; Held U
Cochrane Database Syst Rev; 2023 Sep; 9(9):CD013606. PubMed ID: 37681561
[TBL] [Abstract][Full Text] [Related]
37. Review of guidelines for good practice in decision-analytic modelling in health technology assessment.
Philips Z; Ginnelly L; Sculpher M; Claxton K; Golder S; Riemsma R; Woolacoot N; Glanville J
Health Technol Assess; 2004 Sep; 8(36):iii-iv, ix-xi, 1-158. PubMed ID: 15361314
[TBL] [Abstract][Full Text] [Related]
38. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study.
Wu O; Robertson L; Twaddle S; Lowe GD; Clark P; Greaves M; Walker ID; Langhorne P; Brenkel I; Regan L; Greer I
Health Technol Assess; 2006 Apr; 10(11):1-110. PubMed ID: 16595080
[TBL] [Abstract][Full Text] [Related]
39. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
Williams I; McIver S; Moore D; Bryan S
Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic tests and algorithms used in the investigation of haematuria: systematic reviews and economic evaluation.
Rodgers M; Nixon J; Hempel S; Aho T; Kelly J; Neal D; Duffy S; Ritchie G; Kleijnen J; Westwood M
Health Technol Assess; 2006 Jun; 10(18):iii-iv, xi-259. PubMed ID: 16729917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
